ClinicalTrials.gg
CompletedNCT05778721HYPERSOMNPSYUpdated Oct 23, 2026

Psychiatric Co-morbidities and Socio-demographic Characteristics in Patients With Idiopathic Hypersomnia

An observational study in Idiopathic Hypersomnia, Mood Disorder and Bipolar Disorder, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University Hospital, Toulouse · Observational

How we know

Updated Oct 23, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
22
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Idiopathic Hypersomnia with a site in France — 10 open to participants now, 11 under way, 1 of them phase 3. Idiopathic Hypersomnia · France.

Started
2022
the only one that year
Observational
5 of 18
2 open now
Registered
5th of 18
by date

Among the 18 studies in Idiopathic Hypersomnia with a site in France, this one is the only one that started in 2022, is one of 5 observational ones, and was the 5th registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

10 of the 18 studies in Idiopathic Hypersomnia with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Idiopathic Hypersomnia with a site in France, or all of them as a file.
02

Study summary

This is a study of only patients with idiopathic hypersomnia. It is a rare and still poorly understood pathology. In clinical practice, we have found that the treatment and care offered were not always effective. The idea of this study to improve knowledge of this pathology by studying the demographic characteristics of patients and other co-morbidities, in particular psychiatric patients, to see if we can identify common factor to our patients and useful in their medical care. The main objective of this research is to allow a quantitative study of the demographic and psychiatric characteristics of patients with idiopathic hypersomnia.

03

Conditions studied

  • Idiopathic Hypersomnia
  • Mood Disorder
  • Bipolar Disorder

Keywords

  • demographic characteristic
  • psychiatric morbidity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with idiopathic hypersomnia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients with a diagnosis of idiopathic hypersomnia according to the ICSD 3 criteria and the performance of a 48-hour polysomnography at the Sleep Laboratory, between 2004 and today.

Exclusion criteria

Exclusion Criteria:

  • minors persons and under legal protection persons.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
22 participants (actual)
Patient registry
No

Groups and cohorts

  • adult patients with a diagnosis of idiopathic hypersomnia

    adult patients with a diagnosis of idiopathic hypersomnia according to the International Classification of Sleep Disorders (ICSD 3) criteria and the performance of a 48-hour polysomnography at the Sleep Laboratory, between 2004 and today.

    Other: respond to questionnaires by telephone

Interventions

  • Otherrespond to questionnaires by telephone

    Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score

06

What researchers measure

Primary outcomes

  1. demographic characteristics

    SPAQ questionnaires

    Time frame: day 1

  2. psychiatric characteristics

    SACHS bipolarity index

    Time frame: day 1

07

Study locations

1 site
  • Chu Toulouse
    Toulouse, 31000, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jun 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2022
First posted
Mar 21, 2023
StartActual
Dec 11, 2022
Primary completionActual
Jun 11, 2024
CompletionActual
Jun 11, 2024
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Start date
Dec 16, 2022→Dec 11, 2022
Oct 23, 2026
Primary completion
Jun 16, 2024→Jun 11, 2024 (actual)
Oct 23, 2026
Study completion
Jun 16, 2024→Jun 11, 2024 (actual)
Oct 23, 2026
Enrollment
150 (estimated)→22 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Start date Dec 16, 2022→Dec 11, 2022
    Primary completion Jun 16, 2024→Jun 11, 2024 (now actual)
    Study completion Jun 16, 2024→Jun 11, 2024 (now actual)
    Enrollment 150 (estimated)→22 (actual)
    + 4 other changes: index terms, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05778721
Responsible party
Sponsor
First posted
Mar 21, 2023
Start date
Dec 11, 2022
Primary completion
Jun 11, 2024
Completion
Jun 11, 2024
Last update
Oct 23, 2026

Study contacts

Rachel DEBS, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion